Heat shock factor-1 knockout enhances cholesterol 7α-hydroxylase (CYP7A1) and multidrug transporter (MDR1) gene expressions to attenuate atherosclerosis

Karthikeyan Krishnamurthy1, Shannon Glaser2, Gianfranco D. Alpini2, Arturo J. Cardounel3, Zhenguo Liu1, and Govindasamy Ilangovan1*

1Division of Cardiovascular Medicine, Department of Internal Medicine, Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, USA; 2Research, Central Texas Veterans Health Care System, Scott & White Digestive Disease Research Center, Medicine, Scott and White and Texas A&M Health Science Center, Temple, TX 76504, USA; and 3Department of Anesthesiology, The Ohio State University, Columbus, OH 43210, USA.

E-mail: govindasamy.ilangovan@osumc.edu

Received 22 September 2015; revised 15 April 2016; accepted 27 April 2016; online publish-ahead-of-print 30 April 2016

Time for primary review: 28 days

Aims
Stress response, in terms of activation of stress factors, is known to cause obesity and coronary heart disease such as atherosclerosis in human. However, the underlying mechanism(s) of these pathways are not known. Here, we investigated the effect of heat shock factor-1 (HSF-1) on atherosclerosis.

Methods and results
HSF-1 and low-density lipoprotein receptor (LDLr) double knockout (HSF-1−/−/LDLr−/−) and LDLr knockout (LDLr−/−) mice were fed with atherogenic western diet (WD) for 12 weeks. WD-induced weight gain and atherosclerotic lesion in aortic arch and carotid regions were reduced in HSF-1−/−/LDLr−/− mice, compared with LDLr−/− mice. Also, repression of PPAR-γ2 and AMPKα expression in adipose tissue, low hepatic steatosis, and lessened plasma adiponectins and lipoproteins were observed. In HSF-1−/−/LDLr−/− liver, higher cholesterol 7α-hydroxylase (CYP7A1) and multidrug transporter [MDR1/P-glycoprotein (P-gp)] gene expressions were observed, consistent with higher bile acid transport and larger hepatic bile ducts. Luciferase reporter gene assays with wild-type CYP7A1 and MDR1 promoters showed lesser luminescence than with mutant promoters (HSF-1 binding site deleted), indicating that HSF-1 binding is repressive of CYP7A1 and MDR1 gene expressions.

Conclusion
HSF-1 ablation not only eliminates heat shock response, but it also transcriptionally up-regulates CYP7A1 and MDR1/P-gp axis in WD-diet fed HSF-1−/−/LDLr−/− mice to reduce atherosclerosis.

Keywords
Atherosclerosis • Heat shock factor • Heat shock proteins • Obesity • Glycoproteins

1. Introduction
Heat shock factors (HSFs) are evolutionarily conserved stress response factors that regulate the transcription of heat shock proteins (HSPs) and promote chaperone activity to alleviate proteotoxic stresses in eukaryotic cells. However, more recently, HSF-1 has been found to be an important multifaceted transcription factor that mediates pathogenesis of a variety of diseases such as cardiovascular disorders,1 carcinogenesis,2 drug resistance,3 and neurodegenerative disease.4 Activation of HSF-1 in response to stress is very complex, governed by concerted phosphorylation processes.5 Inactive HSF-1 monomers, present in cytosol as complexes with various endogenous inhibitors, form transcriptionally active trimers upon phosphorylation and bind to heat shock elements (HSE), which comprise a tandem array of inverted repeats of the sequence 5′-nGAAn-3′, in the promoter regions of various HSPs.6 Interestingly, HSEs are present not only in HSP gene promoters, but also in many other gene promoters that are unrelated to the family of HSPs.6 While the classic response of HSF-1 activation is the induction of HSPs, HSF-1 has been found to repress some other gene expressions.7 Therefore, the presence of HSE in many other gene promoters makes understanding the comprehensive regulatory role of HSF-1 in human disease more difficult. In particular, its complex
transcriptional activity in cardiovascular disease remains largely unexplored.

HSF-1 binding to the HSE in the proximal promoter region of multi-drug resistance or transporter gene-1 (MDR1) was found to repress the gene expression by inhibiting NF-kB activity. Furthermore, the lack of HSF-1 was found to increase MDR1 gene expression in the heart of HSF-1 knockout mice, and enhanced P-glycoprotein (P-gp)-based ATP-binding cassette superfamily, subfamily B, member 1 (ABCB1) drug transporter, establishing that HSF-1 is a physiological regulator of cellular drug homeostasis/metabolism. On the other hand, in last few years, a growing body of evidence indicates that MDR1/P-gp enhances dietary cholesterol/lipid metabolism, and dysfunction of P-gp induces metabolic syndrome in animal models and obesity in humans of a specific population. MDR1 knockout mice exhibited higher hepatic steatosis and obesity due to aberrant cholesterol metabolism. Moreover, macrophage cholesterol efflux through other ABC transporters to apolipoproteins A–I was found to reduce atherosclerosis. Since HSF-1 ablation has been shown to induce MDR1 gene expression, HSF-1 is expected to indirectly regulate lipid/cholesterol metabolism by modulating MDR1 gene expression, although no systematic study has been carried out so far to correlate HSF-1 function to dietary cholesterol metabolism in either animal models or humans. Thus, the overall objective of the present study was to determine whether HSF-1 ablation would attenuate atherosclerosis and affect dietary cholesterol metabolism by inducing hepatic MDR1/P-gp gene expression and by proficient P-gp-assisted hepatic bile transport. Using a novel HSF-1 and low-density lipoprotein receptor (LDLr) double knockout (DKO) HSF-1−/−/LDLr−/− mouse model, we report here that HSF-1 deletion reduces atherosclerosis and enhances dietary cholesterol metabolism, by not only inducing hepatic MDR1/P-gp but also by enhancing CYP7A1 gene expression in the liver. Therefore, HSF-1 is found to be a metabolic regulator of dietary cholesterol.

2. Methods

2.1 Animals and diets

LDLr−/− (C57/B16, Jackson Laboratory) and HSF-1−/− (Prof. Benjamin, University of Utah, UT, USA) were crossed to generate HSF-1−/−/LDLr−/− mice. At 8–12 weeks of age, males and females of both genotypes were placed on an atherogenic western diet (WD), chow-modified WD, with 1% cholesterol (TD.90674) for 12 weeks, or continued with normal diet (ND). All the protocols were approved by the Institutional Animal Care and Use Committee and were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (see Supplementary material online, Methods).

2.2 Laser capture microdissection and atheroma gene expression analysis

Both ND- and WD-fed mice aorta were isolated, and then lesion and non-lesion areas were analysed for Hsps mRNA.

2.3 pLenti viral titres and in vitro hepatocytes transductions

Mouse hepatocytes were isolated as described before. Mice were anaesthetized with isoflurane (1–1.5%), secured dorsal side down onto a tray. The abdominal cavity was opened to expose inferior vena cava; cannula was inserted into vena cava and perfused with perfusion medium (~10–15 min), then switched to collagenase solution (~10 min), followed by removal of liver in a petri dish containing perfusion medium II at room temperature and dissociated the liver lobes using forceps. Hepatocyte yield was counted and then plated for culture. Mutant HSF-1 overexpressing lentiviral titres (pBABE-mutHSF-1) were generated from pBABE-HSF-1 (Addgene, Cambridge, MA, USA), using single-step site-directed mutation approach.

2.4 Luciferase reporter gene assays

MDR1 promoter cloned luciferase constructs were generated as we previously described. Mutant Cyp7A1 promoter fragment cloned luciferase construct was generated using wild-type CYP7A1 promoter cloned luciferase (a gift from Prof. J.Y. Chiang, Northeast Medical University, OH, USA). LDLr−/− and DKO hepatocytes were transduced with pGL3-prMDR1-Luc or pGL3-prCYP7A1-Luc as described.

2.5 Immunofluorescence staining of Hsp25

Aortic sections of 4 µm were stained with a mouse primary anti-mouse Hsp25 (sigma) and anti-rabbit α-actin antibody (abcam). Slides were dual-stained using green Alexa Fluor 488 conjugated goat-anti-rabbit secondary antibody and red Alexa Fluor 555 conjugated donkey anti-mouse secondary antibody (Invitrogen). Total RNA was extracted from various tissues of the LDLr−/− and DKO mouse tissue using RT-PCR procedure, provided by the manufacturer (Qiagen). Immunoblotting and electrophoretic mobility shift assay (EMSA) were carried as described in our previous study.

2.6 Statistics

Group comparisons were performed using Student’s t-test for normally distributed data, Mann–Whitney U test for non-normally distributed data, and one- or two-way ANOVA (Sigma Plot 12, Systat). Post hoc analyses of atherosclerotic lesion data were analysed using Tukey’s post hoc analysis. Data are presented as means ± SEM. The general acceptance level of significance was P < 0.05.

3. Results

HSF-1−/−/LDLr−/− DKO mice were generated by crossing HSF-1−/− and LDLr−/− mice and genotyped. The HSF-1−/−/LDLr−/− DKO mice maintained the lean phenotype of HSF-1−/− mice (14.75 ± 1.56 g at the age of 8 weeks). These mice were switched to either WD (starting at the age of 8 weeks) or continued with ND, and body weight gain was followed for 12 weeks. WD-fed DKO mice gained less weight, compared with age-matched LDLr−/− mice (Figure 1A and B). No significant difference in weight gain was observed for ND-fed LDLr−/− and DKO mice. WD-induced weight gain started in LDLr−/− mice as early as third week. Since food intake was comparable among the genotypes (Figure 1C), the difference in the weight gain is not due to hypophagia. Visceral fat deposits, in the form of white adipose tissue (WAT), increased in LDLr−/− group (Figure 1A). The adipose tissue was stained with F4/80 to determine macrophages infiltration (Figure 1D). Qualitative assessment of macrophages showed significantly fewer counts in DKO mice compared with LDLr−/− mice. Adipocyte sizes in WAT, also determined (Figure 1E) from the same images, confirmed that LDLr−/− mice had hypertrophic adipocyte phenotype showing typical large unilobular lipid content in cells (as confirmed by oil-O-red staining, inset in Figure 1D). Adipocyte size distribution showed that adipocytes in DKO mice are smaller (approximately one-third) than the size observed in LDLr−/− mice (Figure 1E). The lower macrophage infiltration in DKO mice is expected to have less cytokines and higher differentiation of adipocytes. However, the macrophages in DKO and LDLr−/− mice could be phenotypically different playing opposite roles, namely inflammatory and anti-inflammatory. Therefore, peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) was used as differentiation marker, as described below, to determine whether the DKO mice have less adipocyte differentiation. We, also, determined whether
the metabolic sensor AMP-activated protein kinase-α (AMPK-α) and the metabolic gene transcriptional activator PPAR-γ2 levels are different, accounting for the difference in the WAT deposition in DKO mice.

In resting conditions, AMPK-α levels in adipose tissue of ND-fed DKO mice were very much reduced, compared with LDLr<sup>2/2</sup> mice (Figure 1F). WD-fed LDLr<sup>2/2</sup> and DKO mice adipose also showed similar trends indicating that there is no AMPK-α alteration due to cholesterol-rich WD feeding in these mice (Figure 1F). Furthermore, AMPK-α activity, as determined from acetyl CoA carboxylase phosphorylation (as detected by phospho-acetyl-CoA carboxylase (p-ACC) antibody, Figure 1F), was consistent with the expression levels. PPAR-γ, a lipid-sensitive nuclear receptor<sup>11</sup> that accounts for a majority of lipid metabolism-related gene transcription, was found in adipose tissues of all the four groups. In ND-fed LDLr<sup>2/2</sup> mice, a significant level of PPAR-γ2 (adipose tissue specific) was observed. However, in DKO mice, PPAR-γ2 expression was attenuated (Figure 1F). The same trend was observed in adipose tissues of WD-fed mice. These results demonstrate that HSF-1 deletion significantly represses PPAR-γ2 expression and activity. Further, plasma-level adipokines (leptin and adiponectin) were measured. In ND-fed LDLr<sup>2/2</sup> mice, leptin level was more than three-fold higher in DKO mice. This was the same in WD-fed groups as well (Figure 1G). Interestingly, total adiponectin (Figure 1H) was lower in ND-fed DKO mice. However, upon feeding with WD, adiponectin level decreased ~75% in LDLr<sup>2/2</sup> mice, but in DKO mice, it increased about two times, an opposite trend in response to high-fat containing WD feeding. Thus, the observed decrease in WAT size and adipose PPAR-γ2 in DKO mice indicate a phenotype of effective systemic dietary cholesterol metabolism through a novel pathway in these mice.

Aortas, isolated from both LDLr<sup>2/2</sup> and DKO mice fed with WD for 12 weeks, were stained with Oil-O-Red for atherosclerotic lesions assessment. Oil-O-Red-stained aortas showed smaller lesions in subclavian, aortic arch, and distal regions in HSF-1<sup>2/2</sup>LDLr<sup>2/2</sup> DKO mice (Figure 2A). Quantitative assessment (Figure 2B) (manual outlining of the lesions from internal elastic lamina to luminal edge) showed 50% reduction in lesion area (<1400 ± 50 pixels in LDLr<sup>2/2</sup> aorta vs. 776 ± 62 pixels in DKO aorta, P < 0.01). These data demonstrate a pronounced reduction in WD-induced atherosclerotic plaque burden.
in DKO compared with LDLr<sup>−/−</sup> mice. There was no significant lesion development in ND-fed mice (Figure 2B), and no sex-related difference in plaque formation was observed. Characterization of atherosclerotic lesions revealed a marked reduction in intimal thickening of aortic walls in DKO mice. H&E staining of the lesion areas of WD-fed mice showed a marked decrease in lipid-rich core in DKO mice (Figure 2C). A marked decrease in positive fibrillar collagen staining (Sirius red) in atherosclerotic plaques of DKO mice was observed compared with the LDLr<sup>−/−</sup> mice (Figure 2D). Similarly, smooth muscle cell α-actin staining also showed a relative decrease in cap thickness in DKO mice, when compared with the LDLr<sup>−/−</sup> mice (Figure 2E). Macrophages are a major source of MMPs within the atherosclerotic plaque, due to arterial wall macrophage infiltration and foam cells. To determine whether HSF-1 activation and subsequent heat shock response (HSR) regulates the accumulation of macrophages in plaques, we examined the atherosclerosis-associated macrophages in the aortic arch by F4/80 staining in these mice. Macrophages were found to be densely distributed throughout the plaque in the LDLr<sup>−/−</sup> mice lesions (Figure 2F), in marked contrast to the DKO mice lesions. These data establish that DKO mice not only maintain a lean phenotype but also develop less atherosclerotic lesions compared with LDLr<sup>−/−</sup> mice. At 12 weeks, plasma-level lipoproteins were determined in the ND- or WD-fed animals of both genotypes. Plasma from WD-fed LDLr<sup>−/−</sup> mice appeared more turbid (Figure 2G) than WD-fed DKO mice, suggesting that overall lipid content was less in WD-fed DKO mice plasma. Lipoprotein determination in plasma revealed that significantly higher levels of lipoproteins were present in the WD-fed mice plasma of both genotypes, compared with the ND-fed mice (Figure 2H–K). However, WD-fed LDLr<sup>−/−</sup> mice showed more than a three-fold increase in plasma lipoprotein levels and cholesterol, compared with ND-fed mice. The DKO mice plasma showed only a smaller increase in lipoproteins and cholesterol compared with LDLr<sup>−/−</sup> mice. Similarly, triglyceride was significantly lower in the DKO mice. These results further substantiate that lower body weight and atherosclerosis in DKO mice are consistent with hyperlipidaemia and hypercholesterolaemia.

Heat shock gene expression was determined using laser capture microscopy in atherosclerotic lesion and in surrounding nearby normal area of the same aorta of both LDLr<sup>−/−</sup> and DKO mice. Figure 3A shows H&E-stained images of cryosections of aorta revealing the area used for mRNA extraction by laser capture. Figure 3B shows the
quantitative estimation (normalized with respect to GAPDH mRNA) of Hsp25 mRNA (as a representative marker of HSR and HSF-1 activation). There was a two-fold increase in Hsp25 mRNA (a marker of HSF-1 activation and an important HSP that regulates many cellular growth factors) in the lesion areas of WD-fed LDLr\(\text{2}^-\)\(\text{2}^-\) mice compared with ND-fed mice. There was almost no change in WD-fed DKO mice, indicating strong HSR and activation of HSF-1 in LDLr\(\text{2}^-\)\(\text{2}^-\) mice lesions favouring the lesion, but in the absence of HSF-1, no such response was observed. These data demonstrate that HSF-1 activation plays an important role in the form of HSR in atherogenesis and its ablation regresses lesion. It is also observed in Figure 3C that in spite of knocking down HSF-1 in DKO, there is still a small increase in HSPs, indicating that there could be secondary mechanism to induce HSPs.

To further characterize the HSR, HSPs were evaluated in lesion and surrounding non-lesion areas of the same aorta by western blotting (Figure 3C). The quantitative estimation (Figure 3D) indicates that there is a statistically significant increase in Hsp25 protein in WD-fed LDLr\(\text{2}^-\)\(\text{2}^-\) mice, corroborated by laser capture mRNA determination (Figure 3A). However, consistent with mRNA data, there is a slight increase, but comparatively very low HSPs were observed in DKO mice (Figure 3D–F). The immunohistochemical staining of Hsp25 was carried out by triple staining [Hsp25, α-actin, and diamidino-2-phenylindole (DAPI)] to confirm the excess Hsp25 in the lesions. Figure 3G shows representative overlapped images of the aorta from ND- and WD-fed LDLr\(\text{2}^-\)\(\text{2}^-\) and DKO mice. As seen, Hsp25 (red channel) was very high in the lesion area of LDLr\(\text{2}^-\)\(\text{2}^-\) mice. However, in DKO mice, there is no significant red fluorescence observed in the lesions, although a small amount was observed in the intima. α-Actin and DAPI-stained nuclei were uniform in all these cases. These results confirm that HSF-1 knockout impairs the lesion by reduced expression of Hsp25, and hence its absence not only helps to reduce WAT, but also attenuates atherosclerosis by inhibiting the HSR during atherogenesis.

We quantified circulating extracellular Hsp25 (eHsp25) in plasma, because overexpression of human Hsp27 and an increase in circulating Hsp27 are reported to be atheroprotective.18 Figure 3H shows western blots (and the quantitative plots, Figure 3I) of circulating extracellular eHsp25 in plasma. However, upon feeding with WD, circulating eHsp25 was increased in the LDLr\(\text{2}^-\)\(\text{2}^-\) whereas an increase is not observed in DKO mice. This suggests a possible role of Hsp25 in the formation/progression of aortic lesions.
WD-fed LDLr<sup>−/−</sup> and DKO mice liver sections were stained with H&E and examined for hepatic steatosis in portal areas and surrounding lobular areas. H&E images showed more and larger intracellular lipid droplets in the centrilobular area of LDLr<sup>−/−</sup> mice compared with DKO mice (Figure 4A), whereas normal hepatocytes were found in peripheral zones. Most of these neutral lipid droplets were observed around microvascular region (Figure 4A inset), suggesting the centrilobular region as a fat storage area. Liver weight was increased ≏20% in WD-fed LDLr<sup>−/−</sup> animals, but there was no significant change in DKO mice (Figure 4B). Masson’s Trichrome staining of liver slices of these two groups showed significant portal tract fibrosis and sclerosing cholangitis in LDLr<sup>−/−</sup> mice (Figure 4C), while the DKO mice hepatocytes were normal. A semi-quantitative estimation (Figure 4D) reveals that fibrosis is significantly higher in LDLr<sup>−/−</sup> mice. Similar to adipose tissue, liver AMPK-α and PPAR-γ were also consistently lower in DKO mice (Figure 4E–H). These results suggest an enhanced hepatic metabolism of dietary cholesterol in DKO mice.

We next examined P-gp expression in the liver tissues of DKO mice. Liver sections stained for P-gp showed increased expression in DKO mice, particularly around portal areas (Figure 5A). Semi-quantitative estimation from western blots (Figure 5B) and mRNA measurements (Figure 5C) confirmed that P-gp level was about two-fold higher in DKO livers, compared with LDLr<sup>−/−</sup> mouse livers. Increased MDR1 gene expression in DKO mouse hepatocytes was further characterized in vitro by a firefly luciferase reporter gene assay. Hepatocytes of both LDLr<sup>−/−</sup> and DKO mice were transfected with MDR1 promoter fragment (−198 to +43) cloned luciferase construct (pMDR1-Luci). Higher luciferase activity was observed in DKO hepatocytes than LDLr<sup>−/−</sup> (Figure 5D and E), likely due to elimination of repressive HSF-1 binding, as this promoter has been shown to have HSE and to repress MDR1 gene expression. However, mutation of HSE (GAACATTCC to GAACCATC) in the MDR1 promoter increased luminescence in LDLr<sup>−/−</sup> hepatocytes, but not in DKO hepatocytes (Figure 5E). To further substantiate this observation, we next determined whether reconstitution of HSF-1 in DKO hepatocytes could restore the LDLr<sup>−/−</sup> phenotype. Full-length wild-type HSF-1 was overexpressed in DKO hepatocytes with pLenti-HSF-1 viral titres. Ectopic overexpression of HSF-1 in DKO hepatocytes significantly reduced MDR1 expression as illustrated in Figure 5F. Furthermore, overexpression of mutant HSF-1 (deleted with 604–948 bases, pLenti-mutHSF-1) was also tested to determine whether it could induce MDR1 expression in LDLr<sup>−/−</sup> hepatocytes (Figure 5G). Overexpression of mutHSF-1 could induce MDR1 in LDLr<sup>−/−</sup> hepatocytes, yielding a dominant negative phenotype, reducing HSF-1 expression and enhanced MDR1 expression.

Another important phenotype, observed with DKO group, was an enlarged gall bladder (about three times larger than LDLr<sup>−/−</sup> group while LDLr<sup>−/−</sup> mice had gallbladder size comparable to its wild-type
littermates), as shown in Figure 6A and B, suggesting that bile acid sequestration is higher in DKO groups. However, there were no detectable gallstones in DKO mice, indicating that the higher bile collection and larger gall bladder do not appear to be due to any disease phenotype. Thus, increased expression of P-gp and higher cholangiocytes differentiation may be key contributors in the observed higher bile collection.

Figure 6B shows no significant difference in faecal bile acid excretion, suggesting that bile acids are re-adsorbed in the intestine. Proliferation of cholangiocytes is expected to increase intrahepatic bile duct mass. Figure 6C shows images of cytokeratin-19 (CK-19), a specific marker of cholangiocytes in bile ducts, in stained liver sections of these two groups. The larger bile ducts (>15 μm) were also found to be higher in DKO groups. Also, the CK-19-positive cholangiocytes were higher in these liver sections. Similarly, quantitation of bile ducts (Figure 6D) showed a three-fold increase in DKO compared with LDLr²⁻/²⁻ mice. Proliferating CK-19-positive cholangiocytes were higher in DKO small bile ducts (<15 μm). Positive proliferating cellular nuclear antigen (PCNA) staining of cholangiocytes in DKO liver tissues was observed (Figure 6E), confirming an active proliferation of cholangiocytes. These results suggest that high-fat diet did not affect cholangiocyte proliferation in these livers. To determine whether there is any difference in faecal excretion of bile acid, mice from LDLr²⁻/²⁻ and HSF-1²⁻/²⁻/LDLr²⁻/²⁻ groups were individually housed and faeces were collected for a week, and bile content in faeces was determined.

To confirm the higher bile acid generation in DKO mice, the expression and activity of Cyp7A1, the key rate-controlling enzyme that converts cholesterol into neutral bile acids, were determined. First, we carried out a reporter gene assay in hepatocytes isolated from ND- and WD-fed mice of both genotypes. The reporter gene assay with CYP7A1 promoter (-198 to +43 bases, pGL3-MDR1-Luci) showed a three-fold increase in DKO, especially in WD-fed mice (Figure 6F). Upon screening the CYP7A1 proximal promoter sequence, we identified a putative HSE-binding site for HSF-1, in the CYP7A1 promoter region (-198 to -2901 bases). We generated a mutant CYP7A1 promoter luciferase construct with deletion of this region and determined luciferase activity in these hepatocytes. The luciferase activity was increased only in LDLr²⁻/²⁻ hepatocytes but not in DKO hepatocytes (Figure 6F), suggesting that HSF-1 binding represses CYP7A1 gene expression. Further studies with EMSA and electrophoretic mobility super-shift assay (EMSSA) assays confirmed HSF-1 binding in the CYP7A1 promoter region. Oligonucleotides corresponding to -922 to -901 bases and reverse complement were used in these assays. As seen in Figure 7A, the addition of nuclear extract from...
LDLr<sup>−/−</sup> mice liver did show a shift, which could be super shifted with HSF-1 antibody. Also pre-incubation of nuclear proteins with HSF-1 antibody, prior to incubation with the oligonucleotides, significantly inhibited band intensity, confirming that HSF-1 could indeed bind to CYP7A1 promoter.

Figure 7B shows the western blots of CYP7A1 in DKO hepatocytes. Higher CYP7A1 was observed in WD-fed DKO mice, conforming that P-gp assisted higher conversion of cholesterol to 7α-hydroxycholesterol through CYP7A1, accounts for the increased cholesterol clearance in these mice. Overall, increased cholesterol esterification through P-gp/CYP7A1 is perhaps a contributor for the lean, less atherogenic phenotype, observed in WD-fed DKO mice.

4. Discussion

We report here that HSF-1 knockout reduces heat shock or stress response (HSR) and increases CYP7A1/MDR1/P-gp gene expression in the liver, increasing bile acid sequestration, hence reducing circulating potent lipoproteins and eliciting less atherosclerosis/lean phenotype in mice. HSF-1 was activated in atherosclerotic lesions due to pro-inflammatory and autoimmune responses during the pathogenesis of atherosclerosis. Oxidized LDL, formed due to excess dietary cholesterol, is known to trigger HSR in arterial wall inducing various HSPs. HSF-1 activation in vivo stimulates cells to produce an array of cytokines and expression of HSPs in human endothelial cells and smooth muscle cells (SMCs). Hsp25 has shown immense variability in the lesion area, intimal tissue underneath the lesion, and surrounding nearby area. The core lesion area was found to have less Hsp25 compared with surrounding nearby areas. However, its importance to the development of lesions is poorly understood. One probable role of Hsp25 may be by enhancing SMC proliferation in lesions after the initiation step. Thus, Hsp25 is likely enhancing plaque stability and fibre formation in the lesion. Circulating eHsp25 is another important HSF-1 target that has been previously studied with relevance to atherosclerosis. In the present work, we observed that feeding LDLr<sup>−/−</sup> mice a WD increased circulating eHsp25, but in atheroprotective DKO mice, there was no such WD-dependent elevation in plasma eHsp25, even though basal level eHsp25 was slightly higher than the LDLr<sup>−/−</sup> mice (Figure 3H and I). This suggests that eHsp25 is protective, but activation of HSF-1 and induction of Hsp25 in a developing lesion increase disease progression, an example of heat shock paradox. Therefore, activation of HSR is a critical step in the overall pathogenesis of atherosclerosis.
The present work indicates that HSF-1 plays a role in regulating dietary cholesterol metabolism, clearly emphasizing that HSF-1 has more complex transcriptional activities, other than just activation of the heat shock genes. We discovered in the present work that HSF-1 knockout increases CYP7A1/MDR1/P-gp gene expression in liver bile acid sequestration. Although ATP-binding cassette-based molecular extrusion pumps such as ABCA1 and ABCG1 have previously been found to regulate atherosclerosis by modulating cholesterol efflux in invading arterial wall macrophages foam cells, there is a controversy whether P-gp (ABCB1) can cause the same effect in invading macrophages. However, a correlation of higher MDR1 expression and lesser the atherosclerosis has been previously reported. It is evident from the present HSF-1 deletion that dietary cholesterol is metabolized effectively in these mice. This is consistent with an enlarged gall bladder and increased bile collection observed in these mice (Figure 6A and B), likely due to enhanced cholesterol esterification followed by increased bile acid generation because of high abundant P-gp in the cholangiocytes. The possibility of inhibition of endogenous de novo lipogenesis being responsible for the reduced hepatic steatosis can be ruled out because Jin et al. have found that HSF-1 deletion did not significantly change lipogenic factors such as SREBP1c, ChREBP, or NLRx under normal conditions. In addition, other studies have shown that hepatic cholesterol esterification is inhibited in MDR1 knockout mice and that cholesterol uptake and esterification have been enhanced in MDR1 overexpressing cells. Therefore, the observed novel phenotypes of reduced visceral fat accumulation and attenuated atherosclerosis in HSF-1 knockout mice are likely due to enhanced cholesterol metabolism, obesity, and atherosclerosis.

As WAT has been shown to function as an endocrine organ, releasing various hormones that regulate lipid metabolism in adipose tissue, the less accumulation of visceral fat in DKO mice (Figure 1) seems to cause a very interesting phenotype of dietary cholesterol metabolism. HSF-1 deletion also showed reduced AMPK-α (Figure 1), which is considered as fuel gauge in adipose tissue controlling adipose function as a metabolic regulator, and it could predispose an organism to the development of obesity. In the present work, PPAR-γ2, an adipose-specific nuclear receptor, was reduced in DKO mice (Figure 1). PPAR-γ2 has been found to alter metabolism leading to various heart disease. This nuclear receptor activation is known to induce various adipose-derived adipokines in concert with other nuclear receptors such as LXR and NXR. The mechanistic details of how HSF-1 deletion down-regulates PPAR-γ2 in adipose tissue are not currently defined. However, a previous study demonstrated that transcriptional down-regulation of PPAR-γ2 by a single nucleotide polymorphism (PPAR-γ2 Pro12Ala) improved insulin sensitivity and reduced myocardial infarction in diabetic patients, suggesting that down-regulation of PPAR-γ in DKO mice (Figure 4E) might be responsible for reduced leptin concentrations in serum and the lean phenotype of these mice (Figure 1A–E). Also lower PPAR-γ2 is consistent with low WAT, as it has been identified as an essential component in overall pre-adipocyte differentiation into WAT. Furthermore, the WD-fed DKO mice had adipose tissue with fewer hypertrophic adipocytes and less hepatic steatosis than LDLr−/− mice (Figures 1E and 5A), indicating that dietary cholesterol is metabolized effectively in these mice. This is consistent with an enlarged gall bladder and increased bile collection observed in these mice (Figure 6A and B), likely due to enhanced cholesterol esterification followed by increased bile acid generation because of high abundant P-gp in the cholangiocytes. The possibility of inhibition of endogenous de novo lipogenesis being responsible for the reduced hepatic steatosis can be ruled out because Jin et al. have found that HSF-1 deletion did not significantly change lipogenic factors such as SREBP1c, ChREBP, or LXRx under normal conditions. In addition, other studies have shown that hepatic cholesterol esterification is inhibited in MDR1 knockout mice and that cholesterol uptake and esterification have been enhanced in MDR1 overexpressing cells. Therefore, the observed novel phenotypes of reduced visceral fat accumulation and attenuated atherosclerosis in HSF-1−/−/LDLr−/− mice are likely due to enhanced cholesterol metabolism, but not to decreased lipogenesis in HSF-1 knockout mice. Moreover, this interpretation perfectly explains the large increase in bile secretion and higher cholangiocytes differentiation forming new bile ducts (Figure 6C and D) in DKO mice, and it supports the conclusion that increased bile secretion improves the digestive/faecal excretion mechanism. In summary, HSF-1 knockout significantly attenuated WD-induced atherosclerosis due to its effect on dietary cholesterol clearance by increasing bile secretion, reducing serum LDL, and reducing WAT accumulation. Deletion of HSF-1 was found to establish the CYP7A1/MDR1/P-gp axis, as
HSF-1 was also found to affect the expression of other transcription factors such as PPAR-γ and metabolic sensor AMPK-α in adipose tissue. Overall, the HSF-1−/−/LDLR−/− DKO mice present with an intriguing but complex phenotype. Although our data indicate that these mice have markedly higher metabolic rate, other possibility such as higher locomotor activity or malabsorption must also be considered for complete understanding of the phenotype. Similarly, although it is difficult to conclude whether HSF-1 deficiency is directly responsible for decreased macrophages in adipose, HSF-1 deletion certainly enhanced the dietary cholesterol clearance. Taken together, this work establishes that inhibition of HSF-1 to prevent adipose tissue accumulation, atherosclerosis, and related vascular complications is a potential future therapeutic approach to treat cardiovascular disease in humans.

Supplementary material
Supplementary material is available at Cardiovascular Research online.

Acknowledgements
We acknowledge Prof. I.J. Benjamin, University of Utah, for providing HSF-1−/− mice. We also thank Ohio State University Campus Microscopy & Imaging Facility (CMIF) and Laser Capture Molecular (LCM) core for their services.

Conflict of interest: none declared.

Funding
This work was supported by the National Institutes of Health (R21HL094881 and R01HL078796-02 to G.J.; and R01HL094650 and R01HL124122 to Z.L.; and VA Merit award (5I01BX002192) to S.G.).

R01HL124122 to Z.L.; and VA Merit award (5I01BX000574) to G.A.; VA Merit Award (5I01BX002192) to S.G.

References